India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements.
No valid response from Gemini.
